公开(公告)号：US20100209480A1

公开(公告)日：2010-08-19

申请号：US12678877

申请日：2008-09-24

申请人： Ralf Altenburger ,  Maggy B. Saunier ,  Nicole Bargenda ,  Michael A. Bock ,  Sabine Adler ,  Bruno Buss ,  Catherine Curdy ,  Indrajit Ghosh ,  Stefan Hirsch ,  Patrice F. Keller ,  Charu Kochhar ,  Shoufeng Li ,  Nicoletta Loggia ,  Amol S. Matharu ,  Julien Taillemite ,  Wei-Qin Tong ,  Sudha Vippagunta ,  Hong Wen ,  Marie-Christine Wolf ,  Jay P. Lakshman ,  James Kowalski

发明人： Ralf Altenburger ,  Maggy B. Saunier ,  Nicole Bargenda ,  Michael A. Bock ,  Sabine Adler ,  Bruno Buss ,  Catherine Curdy ,  Indrajit Ghosh ,  Stefan Hirsch ,  Patrice F. Keller ,  Charu Kochhar ,  Shoufeng Li ,  Nicoletta Loggia ,  Amol S. Matharu ,  Julien Taillemite ,  Wei-Qin Tong ,  Sudha Vippagunta ,  Hong Wen ,  Marie-Christine Wolf ,  Jay P. Lakshman ,  James Kowalski

IPC分类号： A61K31/41 ,  A61K9/70 ,  A61K9/48 ,  A61K9/24 ,  A61K9/14 ,  A61P13/12 ,  A61P9/10 ,  A61P9/04 ,  A61P9/12 ,  B29B9/06

CPC分类号： A61K9/209 ,  A61K9/4808 ,  A61K9/5084 ,  A61K31/165 ,  A61K31/41 ,  A61K45/06 ,  A61K2300/00

摘要： The present invention relates to a pharmaceutical oral fixed dose combination comprising a) a therapeutically effective amount of Aliskiren, or a pharmaceutically acceptable salt thereof, b) a therapeutically effective amount of Valsartan, or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical oral fixed dose combination shows an in vitro dissolution of component a) of 80% or less after 10 minutes and 98% or less after 20 minutes, and a dissolution profile of component b) of 25% or more after 30 minutes, and 40% or more after 60 minutes at pH 4.5.

摘要翻译： 本发明涉及药物口服固定剂量组合，其包含a）治疗有效量的阿利吉仑或其药学上可接受的盐，b）治疗有效量的缬沙坦或其药学上可接受的盐，其中药物口服固定剂量 10分钟后组分a）的体外溶出度为80％以下，20分钟后为98％以下，30分钟后组分b）的溶出曲线为25％以上，40％以上 pH 4.5时60分钟。

公开(公告)号：US20130115253A1

公开(公告)日：2013-05-09

申请号：US13671007

申请日：2012-11-07

申请人： Mahendra R. Patel ,  Amol S. Matharu

发明人： Mahendra R. Patel ,  Amol S. Matharu

IPC分类号： A61K47/48

CPC分类号： A61K9/10 ,  A61K9/0095 ,  A61K9/1617 ,  A61K9/1635 ,  A61K9/1641 ,  A61K9/5047 ,  A61K31/485

摘要： A stabilized pharmaceutical composition comprises a drug-resin complex wherein the resin has been treated with an alkaline material prior to the formation of the drug-resin complex. The drug-resin complex may further be impregnated with an alkalizing agent, L-methionine, an antioxidant agent, or a combination thereof, or be coated with a diffusion barrier. A method of preparation of the pharmaceutical composition is provided.

摘要翻译： 稳定的药物组合物包含药物 - 树脂配合物，其中树脂已经在形成药物 - 树脂复合物之前用碱性材料处理。 药物 - 树脂复合物可以进一步用碱化剂L-甲硫氨酸，抗氧化剂或其组合浸渍，或涂覆有扩散阻挡层。 提供了制备药物组合物的方法。

公开(公告)号：US11826310B2

公开(公告)日：2023-11-28

申请号：US17286535

申请日：2019-10-18

申请人： Amol S. Matharu

发明人： Amol S. Matharu

IPC分类号： A61J3/00 ,  A61L9/14 ,  A61J1/20 ,  B01F33/80 ,  B65B3/00 ,  B65B55/12

CPC分类号： A61J3/00 ,  A61J1/2003 ,  A61L9/14 ,  B01F33/836 ,  B65B3/003 ,  B65B55/12

摘要： A pharmaceutical mobile machine to produce a sterile dosage pharmaceutical form from non-sterile or sterile ingredients amenable for human dosing and administration, The pharmaceutical machine includes an ingredient combiner module including a mixer to mix active and inactive pharmaceutical ingredients and a transfer conduit to transfer the mixed ingredients from the ingredient combiner module. A final product module is operatively connected to the transfer conduit to receive the mixed ingredients from the ingredient combiner module. The final product module includes filling equipment to fill one or more containers to produce the sterile dosage pharmaceutical form. An environment module includes an air purifying system having an outlet operatively connected to the final product module, wherein the air purifying system provides purified air to the final product module through the outlet.

公开(公告)号：US20210386623A1

公开(公告)日：2021-12-16

申请号：US17286535

申请日：2019-10-18

申请人： Amol S. Matharu

发明人： Amol S. Matharu

IPC分类号： A61J3/00 ,  A61L9/14

摘要： A pharmaceutical mobile machine to produce a sterile dosage pharmaceutical form from non-sterile or sterile ingredients amenable for human dosing and administration, The pharmaceutical machine includes an ingredient combiner module including a mixer to mix active and inactive pharmaceutical ingredients and a transfer conduit to transfer the mixed ingredients from the ingredient combiner module. A final product module is operatively connected to the transfer conduit to receive the mixed ingredients from the ingredient combiner module. The final product module includes filling equipment to fill one or more containers to produce the sterile dosage pharmaceutical form. An environment module includes an air purifying system having an outlet operatively connected to the final product module, wherein the air purifying system provides purified air to the final product module through the outlet.